Sanofi and Boehringer Ingelheim to swap businesses
Sanofi and Boehringer Ingelheim have reached an agreement to swap parts of their business.
The swap, between Sanofi’s animal health business and Boehringer Ingelheim’s consumer healthcare business, was initiated in December 2015. The deal is expected to be completed by the end of 2016.
Andreas Barner, chair of the board of Boehringer Ingelheim, said: “This is a win for Boehringer Ingelheim and Sanofi alike. Moreover, it is one of the most significant steps in our corporate history.”
Olivier Brandicourt, chief executive of Sanofi, added: “This business swap will bring a complementary portfolio to our consumer healthcare activity with highly recognised brands, allowing for mid and long term value creation, and enhancement of our market penetration in some major countries.”
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk